Burkitt lymphoma is a highly aggressive B-cell neoplasm. New therapeutic methods are needed to overcome the adverse effect of intensive chemotherapy regimens. Valproic acid and (-)-gossypol are two kinds of chemical compounds used as new anti-tumor drugs in recent years. To investigate the anti-tumor effect of valproic acid and (-)-gossypol, Burkitt lymphoma Namalwa cells were cultured and trea...

Lymphoma is seen in up to 30% of patients with X-linked lymphoproliferative disease (XLP), but cerebral vasculitis related with XLP after cure of Burkitt lymphoma is rarely reported. We describe a case of a 5-year-old boy with XLP who developed cerebral vasculitis two years after cure of Burkitt lymphoma. He had Burkitt lymphoma at the age of 3 years and received chemotherapy (non-Hodgkin's lym...

El linfoma de Burkitt (LB) es un tipo de linfoma no odgkin de células B de crecimiento rápido que afecta niños y adultos jóvenes y que puede presentarse de orma endémica en África, esporádicamente o asociada a nmunodeficiencias. De comienzo brusco y crecimiento agreivo, se produce por la traslocación en el gen c-Myc del romosoma 81. Fue descrito en el año 1958 por el ciruano irlandés Denis Pars...

Chromosomal translocations juxtaposing the MYC protooncogene with regulatory sequences of immunoglobulin (Ig) H chain or kappa (Ig kappa) or lambda (Ig lambda) L chain genes and effecting deregulated expression of MYC are the hallmarks of human Burkitt lymphoma (BL). Here we report that lymphomas with striking similarities to BL develop in mice bearing a mutated human MYC gene controlled by a r...

Burkitt lymphoma is a fast-growing tumor derived from germinal center B cells. It is mainly treated with aggressive chemotherapy, therefore novel therapeutic approaches are needed due to treatment toxicity and developing resistance. Disturbance of red-ox homeostasis has recently emerged as an efficient antitumor strategy. Peroxiredoxins (PRDXs) are thioredoxin-family antioxidant enzymes that sc...

data are lacking. The published series treated with hyper-CVAD rituximab appear to relate to a heterogeneous group of patients of which only one-third had a MYC rearrangement.5 Using the current edition of the WHO classification, it is likely that most of the cases in the Manchester series would be placed in the category “B-cell lymphoma, unclassifiable, with features intermediate between diffu...

Diffuse peritoneal and especially periportal invasion of Burkitt lymphoma is very rarely seen. We present a case 16-year-old boy presenting with abdominal pain constipation, without improvement after enemas. Abdominal ultrasound revealed diffuse infiltrating mass, omental caking, ascites, confirmed by computed tomography (CT). No lymphadenopathies were Biopsy was performed the diagnosis made. A...

We have studied somatic cell hybrids between mouse myeloma cells and IARC-BL2 Burkitt lymphoma human cells carrying a t(8;22) chromosome translocation for the presence and expression of human immunoglobin A chains and for the cmyc oncogene. The results indicate that the c-myc oncogene remains on the 8q+ chromosome and that the excluded and rearranged CA allele translocates from chromosome 22 to...